Shattuck Labs Inc. (STTK) News
Filter STTK News Items
STTK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STTK News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest STTK News From Around the Web
Below are the latest news stories about SHATTUCK LABS INC that investors may wish to consider to help them evaluate STTK as an investment opportunity.
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceAUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San |
Shattuck Labs highlights upcoming key milestones in 2025Shattuck Labs (STTK) announced a corporate update and highlighted upcoming key milestones anticipated in 2025. “We have made considerable progress in the development of our potential first-in-class DR3 blocking antibody, SL-325,” said Taylor Schreiber, M.D., Ph.D., CEO of Shattuck. “Based on observations from our preclinical, non-human primate (NHP) studies, we remain highly optimistic that SL-325 will achieve a more complete blockade of the clinically validated DR3/TL1A signaling pathway and ar |
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced a corporate update and highlighted upcoming key milestones anticipated in 2025. “We have made considerable progress in the development of our potential first-in-class |
Barfresh Food Group And 2 Other US Penny Stocks To ConsiderAs the U.S. stock market navigates a mix of rising Treasury yields and fluctuating indices, investors are keenly observing opportunities for growth amid these dynamic conditions. Penny stocks, while often overlooked, remain an intriguing segment of the market. These stocks typically represent smaller or newer companies and can offer significant growth potential when supported by strong financial health and fundamentals. |
Shattuck Labs Announces Participation in Upcoming December ConferencesAUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced that company management will participate in two investor conferences in December 2024. Presentation DetailsConference: Piper Sandler 36th Annual Healthcare Conferen |
Shattuck Labs Third Quarter 2024 Earnings: Beats ExpectationsShattuck Labs ( NASDAQ:STTK ) Third Quarter 2024 Results Key Financial Results Net loss: US$16.7m (loss narrowed by 40... |
Shattuck Labs sees cash runway into 2027Shattuck has effectuated its restructuring plan to prioritize the development of the DR3 program and align the Company’s cost and workforce structure with the its current goals and clinical development strategy. The Company has substantially completed the reduction in force associated with the discontinuation of SL-172154. Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from its Phase 1 clinical trial of |
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of |
Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a TurnaroundShattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)The heavy selling pressure might have exhausted for Shattuck Labs (STTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |